Back Molteni, M (17 Oct 2023) 'How one scientist's determination made Novo Nordisk an obesity-drug powerhouse', STAT News
PMID:10098504
Tyr 10 Positions 10, 12, 13, and 14 of exenatide (full GLP-1R agonist) are different from those of GLP-1, suggesting that these residues are unimportant to GLP-1
Therefore, the development of an oral delivery strategy for peptide GLP-1R agonists is expected to reduce these adverse effects and improve patient compliance and quality of life (Borner et al., 2020
Before prescribing GLP-1 therapy, our medical professionals will evaluate your medical history, current health conditions, and weight loss goals to determine if this treatment is right for you
GLP-1 Arg 36 replacement with Ala obviously hinders affinity (IC 50 : 0.27 nM4.6 nM) and activity (EC 50 : 2.6 nM7 nM)